Coronavirus

Pfizer Backs Out Of Emergency Use Request For Vaccine In India; Know Why

New Delhi: Pfizer has decided to withdraw the application for emergency use authorisation of its COVID-19 vaccine in India, the pharmaceutical major said on Friday.

Incidentally, the US company was the first firm to seek the emergency use authorisation from the Drugs Controller General of India (DCGI) for its vaccine, after it had secured similar approvals in the UK and Bahrain.

According to sources, Pfizer’s decision to withdraw its application followed a meeting with DCGI’s Subject Expert Committee earlier on Wednesday.

Confirming this, a Pfizer statement said, “Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time.”

The company, however, added that it will resubmit the approval request with additional information in the near future, NDTV reported.

“Pfizer remains committed to making its vaccine available for use by the Government in India and to pursuing the requisite pathway for emergency use authorisation that enables the availability of this vaccine for any future deployment,” the statement said.

Behind The Scenes

Pfizer had sought authorisation for its vaccine in India late last year, but the government in January approved two much cheaper shots — one from Oxford University/AstraZeneca and another developed at home by Bharat Biotech with the Indian Council of Medical Research. Both companies had applied for approval of their vaccines after Pfizer.

Pfizer’s Take

The US company had claimed that its application was supported by data from a global study that showed an overall efficacy rate of 95 per cent with no vaccine-related, serious safety concerns, Reuters reported.

Drugs Controller Stand

However, the Central Drugs Standard Control Organisation had declined to accept Pfizer’s request for approval without a small local trial on the vaccine’s safety and immunogenicity for Indians, according to an India Today report.

Health officials said they generally ask for so-called bridging trials to determine if a vaccine is safe and generates an immune response in Indian citizens whose genetic makeup can be different from people in Western nations.

OB Bureau

Recent Posts

3 People Including 2 Toddlers Killed After Truck Runs Over Labourers Sleeping On Pune Footpath

Pune: Three people, including two toddlers, died on Monday when a dumper truck run over…

12 minutes ago

3 Khalistani Terrorists Involved In Attack On Punjab’s Police Station Killed In Encounter In Uttar Pradesh

Lucknow: Three terrorists accused of lobbing a grenade at a police post in Punjab’s Gurdaspur…

31 minutes ago

Odisha: Malkangiri-Visakhapatnam Air Connectivity May Become A Reality In 2025

Malkangiri: If things go as per plan, flight services between Odisha’s Malkangiri town and Visakhapatnam…

53 minutes ago

Miscreants Attack Man, Kidnap Female Friend In Odisha Capital

Bhubaneswar: Unidentified miscreants allegedly attacked a man and kidnapped his female friend in Maitri Vihar…

1 hour ago

Youth Beaten To Death On Suspicion Of Theft At Shop In Odisha’s Balasore

Balasore: A young man was allegedly beaten to death on the suspicion of having committed…

2 hours ago

When A ‘Powerful Man’s Wife’ Broke Into Varun Dhawan’s House To Elope With Actor!

Mumbai: Bollywood celebrities have often had funny, at times bizarre experiences, mostly involving hero-worshipping, demanding fans.…

15 hours ago

This website uses cookies.